Insilico Medicine Doses First Patient in Phase IIa Trial of Garutadustat for Inflammatory Bowel Disease
Insilico Medicine has dosed the first patient in its Phase IIa clinical trial of Garutadustat, an AI-designed small-molecule therapy being developed for Inflammatory Bowel Disease (IBD), specifically ulcerative colitis. This milestone reflects Insilico’s strategy of using generative artificial intelligence to rapidly discover and optimize drug candidates for complex diseases. Garutadustat is a gut-restricted prolyl hydroxylase (PHD) inhibitor designed to reduce intestinal inflammation while strengthening the gut lining, a key factor in IBD pathology.
The Phase...